Comparing of Innovate Biopharmaceuticals Inc. (INNT) and Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH)

Innovate Biopharmaceuticals Inc. (NASDAQ:INNT) and Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH), both competing one another are Biotechnology companies. We will contrast their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Innovate Biopharmaceuticals Inc. N/A 0.00 23.52M -3.91 0.00
Spring Bank Pharmaceuticals Inc. N/A 0.00 18.89M -1.37 0.00

Demonstrates Innovate Biopharmaceuticals Inc. and Spring Bank Pharmaceuticals Inc. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 demonstrates the return on assets, return on equity and net margins of Innovate Biopharmaceuticals Inc. and Spring Bank Pharmaceuticals Inc.

Net Margins Return on Equity Return on Assets
Innovate Biopharmaceuticals Inc. 0.00% 0% -292.6%
Spring Bank Pharmaceuticals Inc. 0.00% -47.4% -34.4%

Institutional and Insider Ownership

Innovate Biopharmaceuticals Inc. and Spring Bank Pharmaceuticals Inc. has shares held by institutional investors as follows: 11.4% and 42.9%. Insiders held 0.1% of Innovate Biopharmaceuticals Inc. shares. On the other hand, insiders held about 4% of Spring Bank Pharmaceuticals Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Innovate Biopharmaceuticals Inc. 19.23% -22.5% -50.56% -69.87% -49.74% -49.18%
Spring Bank Pharmaceuticals Inc. -9.25% -13.63% -19.94% -26.09% -19.62% -24.11%

For the past year Innovate Biopharmaceuticals Inc.’s stock price has bigger decline than Spring Bank Pharmaceuticals Inc.

Summary

Spring Bank Pharmaceuticals Inc. beats on 5 of the 6 factors Innovate Biopharmaceuticals Inc.

Innovate Biopharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing autoimmune and inflammation therapeutics. Its late-stage clinical pipeline focuses on addressing unmet needs in diseases, such as celiac disease, inflammatory bowel disease (IBD), and nonalcoholic steatohepatitis (NASH). The company's lead drug candidate, larazotide acetate (INN-202), has successfully met its primary endpoint in a Phase 2b efficacy clinical trial for celiac disease. It is also developing INN-108, which is entering into Phase 2 clinical trials for the treatment of mild to moderate ulcerative colitis. In addition, the company owns the global rights to INN-329, a proprietary formulation of secretin, a peptide hormone used to enhance visualization in magnetic resonance cholangiopancreatography procedures. Innovate Biopharmaceuticals, Inc. was founded in 2012 and is based in Raleigh, North Carolina.

Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its SMNH compounds are small segments of nucleic acids that the company designs to target and modulate the activity of specific proteins implicated in various disease states. The companyÂ’s lead product candidate is SB 9200, which completed a Phase 1 clinical trial for the treatment of chronic hepatitis B virus and respiratory syncytial virus. It also develops SMNH product candidate, SB 11285, an immunotherapeutic agent for the treatment of selected cancers; and SB 9400, SB 9941, and SB 9946 preclinical product candidates for viral diseases. The company has an agreement with Arrowhead Pharmaceuticals, Inc. to collaborate on the study of the combined use of SB 9200 and small interfering ribonucleic acid product pipeline for the treatment of chronic hepatitis B virus (HBV); and Arbutus Biopharma Corporation to collaborate on the preclinical study of the combined use of SB 9200 and AB-423, a capsid assembly inhibitor for the treatment of chronic HBV. It also has a clinical trial collaboration agreement with Gilead Sciences, Inc. for a clinical study examining the use of SB 9200 co-administered with GileadÂ’s Vemlidy (tenofovir alafenamide) in chronic HBV patients. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.